Self-lubricating medical articles

Patent metadata

Field	Value
Publication number	US-11613719-B2
Application number	US-201916577824-A
Country	US
Kind code	B2
Filing date	Sep 20, 2019
Priority date	Sep 24, 2018
Publication date	Mar 28, 2023
Grant date	Mar 28, 2023

Abstract

Medical articles formed from a polyurethane-based resin including a modifying oligomer provide enhanced properties. A modifying oligomer incorporated into a backbone, as a side chain, or both of the polyurethane-based resin formed by a diisocyanate, a polyglycol, and a diol chain extender has at least one, preferably two, alcohol moieties (C—OH) and a functional moiety. Exemplary modifying oligomers are: a diol-containing perfluoropolyether incorporated into the backbone, a monofunctional polysiloxane (e.g., monodialcohol-terminated polydimethylsiloxane) incorporated as the side chain, and combinations thereof. Medical articles herein are self-lubricating and/or anti-fouling.

First claim

What is claimed is:

1. A medical article formed from a polyurethane-based resin, which is a reaction product of the following ingredients:
a diisocyanate;
a diol chain extender;
a polyglycol; and
a modifying oligomer incorporated into a backbone, as a side chain, or both of the polyurethane-based resin formed by the diisocyanate, the polyglycol, and the diol chain extender, the modifying oligomer comprising a diol-containing perfluoropolyether incorporated into the backbone, the diol-containing perfluoropolyether having a structure of
HO(CH 2 CH 2 O) p CH 2 CF 2 O(CF 2 CF 2 O) q (CF 2 O) r CF 2 CH 2 (OCH 2 CH 2 ) p OH
wherein p+q+r provide a fluorine content in a range of 55% to 60% by weight and the average molecular weight of the modifying oligomer is in the range of 1500 to 2200 g/mol;
wherein a hard segment content is in the range of from 25% to 75% by weight and a soft segment content of the resin is in the range of from 75% to 25% by weight; and
wherein the medical article is effective as a self-lubricating and/or self-anti-fouling medical article.

2. The medical article of claim 1 , wherein a concentration of the modifying oligomer of the polyurethane-based resin at a surface of the medical article is higher than a theoretical concentration based on uniform distribution of ingredients of the polyurethane-based resin.

3. The medical article of claim 1 , wherein the modifying oligomer further comprises a monofunctional polysiloxane incorporated as the side chain, and combinations thereof.

4. The medical article of claim 1 , wherein the modifying oligomer is present in an amount ranging from about 0.1 to about 10 weight percent of the overall composition of the polyurethane-based resin.

5. The medical article of claim 1 , wherein the diisocyanate is selected from the group consisting of: an aliphatic diisocyanate, alicyclic diisocyanate, and an aromatic diisocyanate.

6. The medical article of claim 5 , wherein the diisocyanate is selected from the group consisting of: 4,4′-diphenylmethane diisocyanate (MDI), toluene diisocyanate (TDI), isophorone diisocyanate (IPDI), and methylene-bis(4-cyclohexylisocyanate) (HMDI), and combinations thereof.

7. The medical article of claim 1 , wherein the diol chain extender is selected from the group consisting of: ethylene glycol, 1,3-propylene glycol, 1,4-butanediol, neopentyl glycol, and alicyclic glycols having up to 10 carbon atoms.

8. The medical article of claim 1 , wherein the polyglycol is selected from the group consisting of: polyalkylene glycol, polyester glycol, polycarbonate glycol, and combinations thereof.

9. The medical article of claim 1 , wherein the polyglycol comprises the polyalkylene glycol.

10. The medical article of claim 1 , wherein the polyalkylene glycol comprises one or both of: a polytetramethylene ether glycol and a polyethylene glycol.

11. The medical article of claim 1 , wherein the polyalkylene glycol comprises a polytetramethylene ether glycol, and a polyethylene glycol that comprises PEG4000.

12. A method of infusion therapy comprising: infusing a material from a medical article according to claim 1 into a patient.

13. The method of claim 12 , further comprising a separate lubricant coated on the medical article.

14. The method of claim 12 , further comprising a separate antifouling agent coated on the medical article.

15. The method of claim 14 , wherein the medical article is effective for a reduced amount of thrombosis formation as compared to a medial article formed from a polyurethane-based resin, which is a reaction product of the following ingredients: a diisocyanate; a diol chain extender; a polyglycol in the absence of a modifying oligomer having an alcohol (C—OH) moiety and a functional moiety; wherein a hard segment content is in the range of from 25% to 75% by weight and a soft segment content of the resin is in the range of from 75% to 25% by weight.

Assignees

• Becton Dickinson Co

Inventors

• Bai He
• Weimer Marc

Classifications

• A61L31/06

  obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds {(A61L31/041 takes precedence)} · CPC title

• C08G18/48

  Polyethers · CPC title

• C08G18/42

  Polycondensates having carboxylic or carbonic ester groups in the main chain · CPC title

• A61L2400/10

  Materials for lubricating medical devices · CPC title

• C08G18/5015

  having fluorine atoms · CPC title